Get a free sample of Central Nervous System Biomarkers Market
Thank you!
Your inquiry has been received. Our team will reach out to you with the required details via email. To ensure that you don't miss their response, kindly remember to check your spam folder as well!
Form submitted successfully!
Error submitting form. Please try again.
Get a free sample of Central Nervous System Biomarkers Market
Thank you!
Your inquiry has been received. Our team will reach out to you with the required details via email. To ensure that you don't miss their response, kindly remember to check your spam folder as well!
Form submitted successfully!
Error submitting form. Please try again.
Central Nervous System Biomarkers Market Size
Central Nervous System Biomarkers Market size was valued at USD 5.6 billion in 2023 and is estimated to grow at a CAGR of 8.1% between 2024 and 2032. Central nervous system (CNS) biomarkers refer to measurable substances or indicators found in biological samples that provide information about the status of the CNS.
These biomarkers can include various molecules, proteins, genes, or other characteristics that are associated with normal CNS function or with the presence, progression, or severity of CNS related diseases. The increasing prevalence of neurological disorders have emerged as a significant driver for the market. For instance, according to the World Federation of Neurology, in 2023, over 40% of the global population is currently suffering from some kind of neurological condition, and this burden is projected to nearly double by 2050.
Furthermore, advancements in the biomarker discovery outsourcing services industry, which is estimated to reach USD 33.7 billion by 2032, are expected to contribute to the CNS biomarkers market growth. These include technological innovations, government initiatives and policies, increasing use of CNS biomarkers, and growing adoption of neurostimulation devices.
What is the size of the North America central nervous system biomarkers market?
North America central nervous system biomarkers industry reached USD 2.3 billion in 2023 and is expected to register a commendable CAGR from 2024-2032 due to the presence of the world's leading research institutions focused on neuroscience and biomarker development in the region.
Why is the demand for central nervous system biomarkers from safety biomarker growing?
The safety biomarker segment recorded USD 2.5 billion in 2023 and is expected to register an appreciable CAGR from 2024-2032 due to their significance in clinical trials to monitor and assess the safety profile of new drugs.
How big is the central nervous system biomarkers industry?
Central nervous system biomarkers market size was USD 5.6 billion in 2023 and is expected to register 8.1% CAGR from 2024-2032 owing to the increasing prevalence of neurological disorders worldwide.
Who are the key players in the central nervous system biomarkers industry?
F. Hoffmann-La Roche Ltd, G-Biosciences, Illumina, Inc., Merck KGaA, Myriad Genetics, Inc., Novartis AG, PerkinElmer Inc., Siemens Healthineers AG, Sysmex Corporation, and Thermo Fisher Scientific Inc., are some of the major central nervous system biomarkers companies worldwide.